[go: up one dir, main page]

NO20041582L - Antistoffinhibitorer av GDF-8 og anvendelse derav - Google Patents

Antistoffinhibitorer av GDF-8 og anvendelse derav

Info

Publication number
NO20041582L
NO20041582L NO20041582A NO20041582A NO20041582L NO 20041582 L NO20041582 L NO 20041582L NO 20041582 A NO20041582 A NO 20041582A NO 20041582 A NO20041582 A NO 20041582A NO 20041582 L NO20041582 L NO 20041582L
Authority
NO
Norway
Prior art keywords
gdf
antibody inhibitors
inhibitors
antibody
Prior art date
Application number
NO20041582A
Other languages
English (en)
Other versions
NO336528B1 (no
Inventor
Denise O'hara
Geertruida M Veldman
N Midlertidig N
Kristie Grove-Bridges
Lisa-Anne Whittermore
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20041582L publication Critical patent/NO20041582L/no
Publication of NO336528B1 publication Critical patent/NO336528B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20041582A 2001-09-26 2004-04-19 Antistoffinhibitorer av GDF-8 og anvendelse derav NO336528B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32452801P 2001-09-26 2001-09-26
PCT/US2002/030452 WO2003027248A2 (en) 2001-09-26 2002-09-26 Antibody inhibitors of gdf-8 and uses thereof

Publications (2)

Publication Number Publication Date
NO20041582L true NO20041582L (no) 2004-04-19
NO336528B1 NO336528B1 (no) 2015-09-21

Family

ID=23263987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041582A NO336528B1 (no) 2001-09-26 2004-04-19 Antistoffinhibitorer av GDF-8 og anvendelse derav

Country Status (16)

Country Link
US (5) US7320789B2 (no)
EP (2) EP1438068B1 (no)
JP (2) JP4452077B2 (no)
AU (1) AU2002347773B2 (no)
BR (1) BR0212809A (no)
CA (1) CA2469230C (no)
DK (1) DK1438068T3 (no)
ES (1) ES2481165T3 (no)
HK (1) HK1064284A1 (no)
MX (1) MXPA04002834A (no)
NO (1) NO336528B1 (no)
NZ (1) NZ532034A (no)
PL (1) PL374221A1 (no)
PT (1) PT1438068E (no)
WO (1) WO2003027248A2 (no)
ZA (2) ZA200402265B (no)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072715A2 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
CA2476654A1 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
WO2004024092A2 (en) * 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
CN1829532A (zh) * 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
SG153874A1 (en) 2003-12-31 2009-07-29 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
JP2007526337A (ja) * 2004-03-02 2007-09-13 アクセルロン ファーマ インコーポレーテッド Ａｌｋ７およびミオスタチン阻害剤ならびにその使用
KR20060133049A (ko) * 2004-03-23 2006-12-22 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
RU2451082C2 (ru) * 2004-08-27 2012-05-20 Вайет Рисёрч Айрлэнд Лимитед Производство полипептидов
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2005323087A1 (en) 2004-12-30 2006-07-13 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
WO2006107611A2 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
BRPI0609449A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
AR053067A1 (es) * 2005-04-25 2007-04-18 Pfizer Anticuerpos contra miostatina
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
AU2006283725B2 (en) 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
EA015589B1 (ru) * 2005-10-06 2011-10-31 Эли Лилли Энд Компани Антитела против миостатина и их применение
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
SG10201509620SA (en) 2005-11-23 2015-12-30 Acceleron Pharma Inc Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
JP5415279B2 (ja) * 2006-12-18 2014-02-12 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
TW201716081A (zh) * 2007-02-01 2017-05-16 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX368173B (es) 2007-02-09 2019-09-23 Acceleron Pharma Inc Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EP3251694A1 (en) 2007-08-03 2017-12-06 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
JP2010539236A (ja) * 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP3415161A1 (en) * 2008-06-26 2018-12-19 Acceleron Pharma Inc. The use of an actriib antagonist for the treatment of anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc METHODS FOR INCREASING ADIPONECTIN
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
KR20210136174A (ko) 2009-06-12 2021-11-16 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
US10704096B2 (en) 2009-07-07 2020-07-07 University Of Southern California Biomarkers for the early detection of autoimmune diseases
KR20200086378A (ko) * 2009-09-09 2020-07-16 악셀레론 파마 인코포레이티드 ＡｃｔＲＩＩｂ 길항제들와 이의 투약 및 용도
JP5836961B2 (ja) * 2009-11-03 2015-12-24 アクセルロン ファーマ， インコーポレイテッド 脂肪肝疾患を処置するための方法
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) * 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
EP2606066A1 (en) 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
SG10201702537RA (en) 2011-07-01 2017-04-27 Amgen Inc Mammalian cell culture
HUE038570T2 (hu) 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
DK2880053T3 (da) 2012-08-01 2020-05-11 Ikaika Therapeutics Llc Lindring af vævsskade og fibrose via anti-LTBP4-antistof
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
LT3564258T (lt) 2012-09-13 2021-08-25 Bristol-Myers Squibb Company Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinu
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
MX376661B (es) 2013-04-02 2025-03-07 Chugai Pharmaceutical Co Ltd Variante de la región fc.
PT2981822T (pt) * 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US10233170B2 (en) * 2014-04-08 2019-03-19 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016081364A1 (en) 2014-11-21 2016-05-26 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
EA037112B1 (ru) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Ингибиторы tgf-
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
IL255010B2 (en) 2015-04-15 2024-01-01 Regeneron Pharma Methods for increasing strength and functionality with GDF8 inhibitors
KR20250033313A (ko) * 2015-09-15 2025-03-07 스칼러 락, 인크. 항-프로/잠재성-미오스타틴 항체 및 그의 용도
JP6142069B1 (ja) * 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
MY199499A (en) 2016-06-13 2023-11-01 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
TW202228778A (zh) 2016-06-17 2022-08-01 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法
EP3788076A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Antibodies with modulated glycan profiles
CA3123024A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
AU2023347206A1 (en) 2022-09-21 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040181A1 (en) * 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6096506A (en) * 1993-03-19 2000-08-01 The Johns Hopkins University School Of Medicine Antibodies specific for growth differentiation factor-8 and methods of using same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4950221A (en) * 1986-07-18 1990-08-21 Gordon Robert T Process for affecting molecules in tissue
US5308752A (en) * 1990-05-23 1994-05-03 Univ. Of Iowa Research Foundation Diagnosis of autosomal muscular dystrophy
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
ES2213745T3 (es) 1993-05-12 2004-09-01 Genetics Institute, Llc Composiciones de bmp-11.
DE69434739T2 (de) 1993-08-26 2007-05-10 Genetics Institute, LLC, Cambridge Menschliche Knochen-morphogenetische Proteine zur Verwendung bei neuronaler Rehgeneration
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
ES2251721T3 (es) 1994-07-08 2006-05-01 The Johns Hopkins University School Of Medicine Factor-11 de diferenciacion del crecimiento.
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US7393528B2 (en) * 1997-01-09 2008-07-01 Tvedten Stephen L Biological pesticide
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU756620B2 (en) 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999024057A2 (en) 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
EP1075272B1 (en) 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
EP1105477A1 (en) 1998-08-20 2001-06-13 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
IL146845A0 (en) 1999-07-20 2002-07-25 Pharmexa As Method for down-regulating gdf-8 activity
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072715A2 (en) 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
WO2004024092A2 (en) 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US6696367B1 (en) 2002-09-27 2004-02-24 Asm America, Inc. System for the improved handling of wafers within a process tool
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
US7261717B2 (en) * 2003-09-11 2007-08-28 Skeletal Kinetics Llc Methods and devices for delivering orthopedic cements to a target bone site
BRPI0609449A2 (pt) 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
WO2006107611A2 (en) 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096506A (en) * 1993-03-19 2000-08-01 The Johns Hopkins University School Of Medicine Antibodies specific for growth differentiation factor-8 and methods of using same
WO1999040181A1 (en) * 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8

Also Published As

Publication number Publication date
MXPA04002834A (es) 2005-09-28
US20120107928A1 (en) 2012-05-03
WO2003027248A8 (en) 2004-04-22
US8710202B2 (en) 2014-04-29
ZA200402265B (en) 2007-03-28
US20150024484A1 (en) 2015-01-22
US20030138422A1 (en) 2003-07-24
US20110020330A1 (en) 2011-01-27
HK1064284A1 (en) 2005-01-28
EP1438068A4 (en) 2005-11-16
JP2009067798A (ja) 2009-04-02
EP1438068B1 (en) 2014-05-21
AU2002347773B2 (en) 2008-03-13
US7320789B2 (en) 2008-01-22
EP1438068A2 (en) 2004-07-21
DK1438068T3 (da) 2014-06-30
CA2469230A1 (en) 2003-04-03
CA2469230C (en) 2017-02-21
ES2481165T3 (es) 2014-07-29
JP2005510212A (ja) 2005-04-21
ZA200606082B (en) 2008-10-29
NO336528B1 (no) 2015-09-21
WO2003027248A3 (en) 2003-05-30
US9505831B2 (en) 2016-11-29
EP2316851A1 (en) 2011-05-04
NZ532034A (en) 2006-06-30
PL374221A1 (en) 2005-10-03
US8092798B2 (en) 2012-01-10
PT1438068E (pt) 2014-07-24
JP4452077B2 (ja) 2010-04-21
WO2003027248A2 (en) 2003-04-03
US7731961B1 (en) 2010-06-08
BR0212809A (pt) 2005-12-13

Similar Documents

Publication Publication Date Title
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20041272L (no) Tetracycline derivatives and methods of use thereof
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DE602004016970D1 (de) P38 inhibitor und anwendungsverfahren dafür
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
DE60234125D1 (de) E inhibitoren
NO20030725D0 (no) Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
ID30187A (id) Dongkrak jenis pantagraf
NO20011026D0 (no) Matvare og fremgangsmÕte for fremstilling derav
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
NO20041968L (no) Anvendelse av cystationin
NO20030843D0 (no) Anordning og fremgangsmåte for kultivering
IS7128A (is) Hreinsun á zaleploni og kristölluð form þess
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
MM1K Lapsed by not paying the annual fees